Research Assessment Seeks Evidence to Guide Treatment of MPN With COVID-19
Investigators assessed studies for evidence to guide the management of MPN in patients with COVID-19.
Myeloproliferative Neoplasms
Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
Disease Features in Young Patients With Myeloproliferative Neoplasms
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Myeloproliferative Neoplasms: What Your Patients Need to Know
Myeloproliferative neoplasms (MPN) are a rare form of blood cancer. Though most people don’t know a lot about, approximately 20,000 people develop MPNs each year. Here are the basics you can explain to a concerned patient.
Mortality Risk With COVID-19 in Patients With Myeloproliferative Neoplasms
Observational, retrospective study revealed factors that may be linked to higher mortality risk in patients with MPN and COVID-19.
Carriers of CALR Mutations at Decreased Risk for Thrombotic Events Among Patients With Essential Thrombocythemia
Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.
Pegylated Interferon Controlled Extreme Thrombocytosis, Well-Tolerated in Younger Patients With MPN
A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.
- Loading...
Loading...
Next post in Multiple Myeloma
Loading... 
Loading...